52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Aug 9 (Reuters) - OncoTherapy Science Inc <4564.T>:Says the company hereby announces that, aiming to accelerate the Cancer Precision Medicine, unit Cancer Precision Medicine, Inc. (CPM) has agreed on a research collaboration with SECOM Medical System Co., Ltd. and Yotsuya Medical Cube about liquid biopsy study for the early detection of cancer.
March 1 (Reuters) - OncoTherapy Science Inc <4564.T>:Says co's unit Cancer Precision Medicine signs joint development agreement with Japanese Foundation For Cancer Research.Says two entities will cooperate on development of genetic variation in cancer .
Feb 15 (Reuters) - OncoTherapy Science Inc <4564.T>:Says its unit, Cancer Precision Medicine forms business alliance with Thermo Fisher Scientific .Says two entities mainly cooperate on evaluation of liquid biopsy platform based on Ion Torrent Oncomine Pan-Cancer Cell-Free Assay .
Aug 2 (Reuters) - OncoTherapy Science Inc <4564.T>:* Says peptide vaccine related agreement with.
July 13 (Reuters) - OncoTherapy Science Inc <4564.T>:* Says it received a patent (No.6159948 )for MELK specific inhibitors in Japan.
July 12 (Reuters) - OncoTherapy Science Inc <4564.T>:* Says it will establish a wholly owened subsidary on July 24.* Say it will transfer research and development of cancer immunotherapy related business to the subsidiary, effective Nov. 1 .* The subsidary will issue 150 new shares to Theragen Etex Co., Ltd. <066700.KQ>, at the price of 1 million yen per share, or 150 million yen in total, and payment date on Aug. 7 .* Theragen Etex Co., Ltd. will acquire 310 shares of the subsidiary, at the price of 1 million yen, for 310 million yen in total, from the co, effective Nov. 15 .* Say the co and Theragen Etex Co., Ltd. Will hold a 64 percent stake and a 36 percent stake finally .
OncoTherapy Science Inc <4564.T> : Says co appoints Kazuo Yamamoto as new president, replacing Masaharu Mori who resigns .Change will be effective on Feb. 27.
OncoTherapy Science Inc <4564.T>: Says Phase 1 trial of OCV-C02, a peptide vaccine for metastatic colorectal cancer patients refractory to all standard chemotherapies .Says OCV-C02 at 0.3 to 6 mg/body exhibited a safe and well tolerated profile, and showed immunological responses in mCRC pts refractory to all standard chemotherapies.
Onco Therapy Science Inc <4564.T>:Says the co will conduct Phase I clinical study of OTS167, a MELK specific inhibitor, for breast cancer patients following the acceptance of the protocol by the U.S. Food and Drug Administration.
OncoTherapy Science Inc <4564.T>:Says the first patient has been enrolled in Phase I/II clinical study of OTS167, an MELK-specific inhibitor, for Acute Myeloid Leukemia.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.